Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theo Rispens

Showing results (161-170 of 304) with videos related to

Pageof 31
Sort By:
Clinical Immunology (Orlando, Fla.)|January 22, 2017
From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switchAndrea Harrer, Georg Pilz, Katrin Oppermann, et al.
Pharmaceutics|March 29, 2023
Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment-TUMMY StudyMerve Sivridaş, Rob H Creemers, Dennis R Wong, et al.
RMD Open|October 6, 2025
Polyclonal Vβ21.3 expansion in multisystem inflammatory syndrome in children despite SARS-CoV-2 vaccinationStejara Netea, Liliane Khoryati, Sietse Nagelkerke, et al.
Clinical Chemistry and Laboratory Medicine|February 11, 2018
Clinically relevant discrepancies between different rheumatoid factor assaysWillem J J Falkenburg, Helen J von Richthofen, Jana Koers, et al.
Therapeutic Drug Monitoring|November 5, 2025
To Convert or Not to Convert? Official International Association of Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Considerations and Recommendations for Converting Capillary Blood Microsampling Concentrations to Plasma ConcentrationsLaura Boffel, Hanna De Baets, Liesl Heughebaert, et al.
Trials|June 20, 2021
Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trialMaike H M Wientjes, Sadaf Atiqi, Gerrit Jan Wolbink, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 16, 2024
Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategyPatricia Resa-Infante, Itziar Erkizia, Xabier Muñiz-Trabudua, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 15, 2023
Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot StudyPaul A G de Klaver, Ron J Keizer, Rob Ter Heine, et al.
Journal of Gastroenterology and Hepatology|October 23, 2018
Unique patterns of glycosylation in immunoglobulin subclass G4-related disease and primary sclerosing cholangitisEmma L Culver, Fleur S van de Bovenkamp, Ninotska I L Derksen, et al.
Pharmaceuticals (Basel, Switzerland)|October 29, 2025
The Association Between Serum Drug Concentration and a Flare in Rheumatoid Arthritis Patients Tapering TNF InhibitorsZohra Layegh, Femke Hooijberg, Laura Boekel, et al.
Pageof 31

Showing results (161-170 of 304) with videos related to

Sort By:
Pageof 31
Clinical Immunology (Orlando, Fla.)|January 22, 2017
From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switchAndrea Harrer, Georg Pilz, Katrin Oppermann, et al.
Pharmaceutics|March 29, 2023
Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment-TUMMY StudyMerve Sivridaş, Rob H Creemers, Dennis R Wong, et al.
RMD Open|October 6, 2025
Polyclonal Vβ21.3 expansion in multisystem inflammatory syndrome in children despite SARS-CoV-2 vaccinationStejara Netea, Liliane Khoryati, Sietse Nagelkerke, et al.
Clinical Chemistry and Laboratory Medicine|February 11, 2018
Clinically relevant discrepancies between different rheumatoid factor assaysWillem J J Falkenburg, Helen J von Richthofen, Jana Koers, et al.
Therapeutic Drug Monitoring|November 5, 2025
To Convert or Not to Convert? Official International Association of Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Considerations and Recommendations for Converting Capillary Blood Microsampling Concentrations to Plasma ConcentrationsLaura Boffel, Hanna De Baets, Liesl Heughebaert, et al.
Trials|June 20, 2021
Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trialMaike H M Wientjes, Sadaf Atiqi, Gerrit Jan Wolbink, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 16, 2024
Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategyPatricia Resa-Infante, Itziar Erkizia, Xabier Muñiz-Trabudua, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 15, 2023
Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot StudyPaul A G de Klaver, Ron J Keizer, Rob Ter Heine, et al.
Journal of Gastroenterology and Hepatology|October 23, 2018
Unique patterns of glycosylation in immunoglobulin subclass G4-related disease and primary sclerosing cholangitisEmma L Culver, Fleur S van de Bovenkamp, Ninotska I L Derksen, et al.
Pharmaceuticals (Basel, Switzerland)|October 29, 2025
The Association Between Serum Drug Concentration and a Flare in Rheumatoid Arthritis Patients Tapering TNF InhibitorsZohra Layegh, Femke Hooijberg, Laura Boekel, et al.
Pageof 31